Les archives familiales d'Agay et la période révolutionnaire

Agay Frédéric d'. Les archives familiales d'Agay et la période révolutionnaire. In: La Gazette des archives, n°146-147, 1989. Archives et révolution : création ou destruction ? (actes du colloque organisé par l’AAF, groupe régional Provence-Alpes-Côte-d’Azur, Châteauvallon, 10-11 mars 1988) pp. 330-337

Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge

International audienceEfficacy, safety and economic issues are the main factors influencing the use of inflammatory bowel disease [IBD]-related medications. The best level of evidence comes from randomised clinical trials. The benefit of the intervention observed in a clinical trial could be reduced once it is implemented in clinical practice: its real-life efficacy, known as effectiveness, could be questioned. That is why effectiveness research based on observational studies is required to obtain-long term data on natural history, including surgery or hospitalisation, and safety. Before starting these real-life studies, it is crucial to be aware of the inherent risks of bias and confounding, to develop a good study plan, and to select the optimal design. Even if the choice of the design is optimal and if the risks of bias and confounding are minimised, the implementation of robust statistical methodology is necessary to increase the validity of the results and allow their dissemination into clinical practice. The objective of this paper is to highlight some inherent methodological problems in effectiveness research and to review some statistical tools with a focus on IBD studies and trials

Fermentation in vivo et in vitro d'un amidon resistant et du lactulose par la microflore colique humaine

National audienc

Characteristics of starch escaping to small intestine digestion and its in vitro and in vivo fermentation

International audienc

In vivo and in vitro fermentation of resistant starch and lactulose by human colonic microflora

Proceedings of the Annual Symposium on NutritionInternational audienc

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study

INTRODUCTION: A study has been developed to assess the use and effectiveness of budesonide MMX for mild-to-moderate active ulcerative colitis (UC) in routine clinical practice. METHODS AND ANALYSIS: A prospective, multicentre, observational, cohort study of 300 patients prescribed budesonide MMX for the treatment of mild-to-moderate active UC will be conducted in Europe, Israel and Canada. Patients will be treated with budesonide MMX9 mg daily for induction of remission for ≤8 weeks. Data on effectiveness, including patient-reported outcomes, tolerability and use will be recorded at the end of treatment and at ≥2 weeks after. The primary outcome (improvement ≥3 point in the clinical subscores of the UC Disease Activity Index score at the end of treatment) will be compared in: patients who receive budesonide MMX added to mesalazine >2 weeks after increased/optimised mesalazine dose for the treatment of flare (late add-on); patients who receive budesonide MMX added to mesalazine ≤2 weeks since mesalazine increased/optimised for the treatment of flare, or without mesalazine dose modification (early add-on); and patients who receive budesonide MMX as monotherapy for the treatment of flare (mono). Propensity scoring will be used to minimise bias and confounding inherent in observational studies. ETHICS AND DISSEMINATION: First ethical approval: Ethikkommission der Ärztekammer Hamburg (12/22/2015). The results will be published in full. DISCUSSION: Completion of primary data collection is expected in December 2017. Our results will provide further evidence on the effectiveness of budesonide MMX to support clinicians in their daily practice and inform therapeutic guidelines. TRIAL REGISTRATION NUMBER: NCT02586259